ARVs, short for antiretrovirals, are medications that treat HIV by stopping the virus from copying itself inside your body. They don’t cure HIV, but they can reduce the amount of virus in your blood to undetectable levels, typically within one to six months of starting treatment. At that point, the virus can no longer damage your immune system, and according to the CDC, a person with a consistently undetectable viral load has zero risk of sexually transmitting HIV to a partner.
How ARVs Work
HIV hijacks your immune cells to reproduce. It latches onto a type of white blood cell, inserts its genetic material, and uses the cell’s machinery to make copies of itself. Those copies then break free and infect more cells. Left unchecked, this cycle gradually destroys the immune system.
ARVs interrupt this cycle at specific stages. Some block the virus from entering your cells in the first place. Others prevent it from converting its genetic code into a form your cells can read. Still others stop the virus from stitching its DNA into your cell’s own DNA, or prevent newly made virus particles from maturing into infectious copies. By combining drugs that work at different stages, treatment makes it extremely difficult for HIV to find a workaround. If the virus develops resistance to one drug, the others still block it.
The Main Drug Classes
There are eight recognized classes of ARVs, each named for the step in HIV’s life cycle it targets:
- NRTIs (nucleoside reverse transcriptase inhibitors) slip into the virus’s growing DNA chain and act as dead ends, stopping the chain from being completed.
- NNRTIs (non-nucleoside reverse transcriptase inhibitors) attach to the same enzyme but at a different spot, changing its shape so it can no longer function.
- Protease inhibitors block the virus from cutting its raw proteins into the pieces needed to assemble new, functional virus particles. The result is immature copies that can’t infect anything.
- Integrase inhibitors (INSTIs) prevent HIV from inserting its DNA into your cell’s chromosomes.
- Fusion inhibitors stop the virus from physically merging with your cell membrane.
- CCR5 antagonists block a specific doorway on the surface of immune cells that HIV uses to get inside.
- Post-attachment inhibitors interfere after the virus has docked onto a cell but before it enters.
- Capsid inhibitors target the protein shell surrounding HIV’s genetic material.
In practice, most people don’t need to know which class their pills belong to. Your regimen will typically combine two or three drugs, often packaged in a single daily tablet.
Current Recommended Regimens
The World Health Organization recommends regimens built around an integrase inhibitor called dolutegravir as the preferred starting treatment for most adults. When a protease inhibitor is needed instead, darunavir-based combinations are now the first choice, replacing older options. For people who struggle with taking pills every day, long-acting injectable ARVs given every one to two months are an option in certain cases. Two-drug oral regimens are also available for people who are already stable on treatment and want to simplify.
ARVs for Prevention, Not Just Treatment
The same drugs used to treat HIV also work to prevent it. There are two main approaches.
PrEP (pre-exposure prophylaxis) is for people who don’t have HIV but face a higher risk of getting it. It can be taken as a daily pill or as an injection every two to six months. If you’re exposed to HIV while on PrEP, the drug prevents the virus from establishing an infection.
PEP (post-exposure prophylaxis) is emergency prevention. If you think you were exposed to HIV through sex, a needle stick, or another route, PEP must be started within 72 hours. You take the medication daily for 28 days. PEP is not designed for repeated use. If you’re frequently at risk, PrEP is the better option.
What to Expect With Side Effects
Modern ARVs are far better tolerated than earlier generations. In clinical trials of newer drugs, fewer than 10% of people experienced side effects serious enough to switch medications. Early on, some people notice nausea, headaches, or fatigue, but these often fade within a few weeks.
Long-term management has shifted toward watching for subtler, slower-developing issues: changes in cholesterol and blood sugar, reduced bone density, kidney strain, and in some cases mood or sleep disturbances. These aren’t inevitable. They vary by drug and by person, and doctors can often switch to a different medication if a problem emerges. Serious reactions like severe allergic responses or liver toxicity are rare but require an immediate change in regimen.
Some older ARVs, many of which are no longer commonly prescribed, caused more noticeable problems like fat redistribution and nerve damage. People who took those drugs years ago may still experience lasting effects even after switching to newer medications.
Why Adherence Matters
ARVs only work if you take them consistently. A minimum of about 85% adherence is typically needed to keep the virus suppressed, though aiming higher gives the best protection. Missing doses gives HIV a chance to reproduce, and when it does, it can develop mutations that make it resistant to your current drugs. Once resistance develops, those medications stop working, and your options narrow.
This is one reason treatment regimens have been simplified over the years. What once required handfuls of pills on strict schedules is now often a single tablet once a day, or for some people, a monthly or bimonthly injection.
Life Expectancy on Treatment
Starting treatment early and staying on it changes the outlook dramatically. A large collaborative study published in The Lancet HIV analyzed over 200,000 people with HIV in Europe and North America. For a 40-year-old woman who started treatment after 2015 with a healthy immune cell count, the estimated remaining life expectancy was about 42 years, meaning she could expect to live into her early 80s. For men in the same situation, the estimate was around 39 additional years.
Starting treatment later, when the immune system is already heavily damaged, shortens that outlook considerably. A 40-year-old man who began ARVs with very low immune cell counts had roughly 24 years of life remaining, compared to 39 years for someone who started with counts in the healthy range. This is one of the strongest arguments for early diagnosis and prompt treatment: the sooner you start, the closer your life expectancy gets to that of someone without HIV.